ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Cardioprotective effects of hesperidin-loaded biodegradable mesoporous copper to reduce cardiomyocyte apoptosis for myocardial infarction.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction (MI) is recognized by its rapid onset and higher mortality rate. The intricate nature of its pathological process has rendered targeted therapy for MI a persistent issue. Hesperidin (HES) has been identified that may protect cardiac cells and promote myocardial tissue regeneration. Nonetheless, its effectiveness in addressing MI-related ischemia situations is hindered by its insufficient angiogenesis and poor bioavailability. This present investigation demonstrates that the effective therapy of HES is augmented by mesoporous copper carbonate (MCC) microspheres, owing to their superior drug-delivery capacity and consistent release of angiogenic degradation (Cu). The cellular examinations demonstrated that HES and Cu could produce synergic effects on endothelial cell angiogenesis and anti-cardiomyocyte apoptosis. Additionally, an in vivo MI model showed that the HES-loaded MCC (MCC@HES) significantly reduced cardiomyocyte apoptosis, decreased infarct size, and enhanced vascularization in myocardial tissue. Overall, the present study is groundbreaking for indicating the benefits of integrating HES with MCC nanocarriers for myocardial remodeling and for presenting an innovative, meticulously designed MCC@HES system as a prospective treatment approach for MI.
Indexed as
Identifiers
41935995What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.